Research Article Details
| Article ID: | A27135 |
| PMID: | 20469672 |
| Source: | Eksp Klin Gastroenterol |
| Title: | [Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy]. |
| Abstract: | AIM: to study the clinical, functional and morphological features of the liver damage in patients with nonalcoholic fatty liver disease in combination with the atherogenic dyslipidemia and/or insulin resistance, and treatment of these changes according to violations. MATERIALS AND METHODS: 240 patients with clinical signs of non-alcoholic fatty liver disease, who were gathering medical history, blood chemistry, lipid spectrum estimation blood, an oral glucose tolerance test, determination of Noma-test, transabdominal ultrasonography of abdominal organs, morphological study of liver with followed morphometric evaluation of the material. RESULTS: The patients with non-alcoholic fat liver disease transaminase levels were ranged from 1.5 to 5. Degree of morphological ethical changes depends on the non-alcoholic fat liver disease etiology, in patients with impaired carbohydrate metabolism was increased dyslipidemia. At patients with IR there were identified morphological changes such as presence of "vacyolelike" nuclei and anisocarosis. In patients with atherogenic dyslipidemia most characteristic histological change is the polymorphism of the nuclei. CONCLUSION: The clinical picture of non-alcoholic fat liver disease is unspecific, without reliable clinical distinction between groups of patients with dyslipidemia, impaired glucose tolerance and patients with diabetes mellitus 2-nd type. Biochemical and morphological changes in the liver are most pronounced in patients with diabetes mellitus 2-nd type. Treatment of the non-alcoholic fat liver disease should be taking into account of the disease etiology (the presence of dyslipidemia or insulin resistance). |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |